Page last updated: 2024-11-05

trihexyphenidyl and Galactosemias

trihexyphenidyl has been researched along with Galactosemias in 1 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Galactosemias: A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)

Research Excerpts

ExcerptRelevanceReference
"Classical galactosemia is an autosomal recessive inborn error of metabolism leading to toxic accumulation of galactose and derived metabolites."1.39Movement disorders in adult patients with classical galactosemia. ( Bhatia, KP; Burke, D; Carecchio, M; Chandrashekar, HS; Edwards, MJ; Footitt, EJ; Kojovic, M; Lachmann, RH; Murphy, E; Parees, I; Rubio-Agusti, I, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rubio-Agusti, I1
Carecchio, M1
Bhatia, KP1
Kojovic, M1
Parees, I1
Chandrashekar, HS1
Footitt, EJ1
Burke, D1
Edwards, MJ1
Lachmann, RH1
Murphy, E1

Other Studies

1 other study available for trihexyphenidyl and Galactosemias

ArticleYear
Movement disorders in adult patients with classical galactosemia.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:6

    Topics: Adult; Anti-Dyskinesia Agents; Benzamides; Botulinum Toxins; Brain; Cross-Sectional Studies; Databas

2013